Products V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 Phase 3 Completed 📈 Rising Prevention of Ebola Infection
Prevention of Ebola Infection
Aug 17, 2015 → Sep 29, 2017
About V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 is a phase 3 stage product being developed by Merck for Prevention of Ebola Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02503202. Target conditions include Prevention of Ebola Infection.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02503202 Phase 3 Completed Aug 17, 2015 Sep 29, 2017 Prevention of Ebola Infection
Product Company Stage Hype Score edoxaban + enoxaparin sodium Daiichi Sankyo Phase 3 Mifepristone Eli Lilly Phase 2 EXANTA AstraZeneca Phase 2 Risk of low dose aspirin discontinuation AstraZeneca Pre-clinical DAPA/MET XR + DAPA + MET XR AstraZeneca Phase 3 Esomeprazole + Placebo AstraZeneca Phase 3 PCV15 Merck Pre-clinical Raltegravir Merck Approved RotaTeq (V260) + IPV Merck Phase 3 V501 Merck Phase 3 Zostavax Merck Phase 3 Letermovir + Placebo Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Enteric-coated mycophenolate sodium Novartis Phase 3 Meningococcal C conjugate vaccine Novartis Approved rMenB+OMV NZ Novartis Phase 3 Enteric-Coated Mycophenolate Sodium Novartis Phase 3 Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml Novartis Phase 3 Meningococcal C Conjugate Vaccine Novartis Phase 3 MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine) Novartis Phase 2
Other Products from Merck